ArticleBone marrow transplantation2026

Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working Party.

Gesine Bug et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.